Stock Monitor: Aclaris Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want access to our free research report on Aimmune Therapeutics, Inc. (NASDAQ: AIMT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AIMT as the Company's latest news hit the wire. On May 30, 2018, the Company announced that it presented data from a new study on the psychosocial burden of peanut allergy in European countries at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in Munich. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Aclaris Therapeutics, Inc. (NASDAQ: ACRS), which also belongs to the Healthcare sector as the Company Aimmune Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ACRS

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Aimmune Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AIMT

Data Discussed Revealed Uncertainty, Bullying, and High Levels of Anxiety around Food

The Allergy to Peanuts Impacting Emotions and Life (APPEAL) study is a multi-dimensional, multi-phase effort, led by the Company in partnership with an expert panel of European food allergy patient advocacy group leaders and healthcare professionals to learn about the psychosocial burden of peanut allergy. The study was conducted in eight European countries, and collected 1,846 responses from 546 peanut-allergic children (as reported by a parent or caregiver), 881 parents or caregivers, and 419 peanut-allergic adults.

In the quantitative online survey, the APPEAL study examined the impact of peanut allergy on peanut-allergic children, parents, and caregivers of peanut-allergic children, and peanut-allergic adults. The survey results showed that peanut allergy has a daily impact on more than 80% of those children, parents/caregivers, and adults, and 40% live with a high level of uncertainty. Additionally, 77% of peanut-allergic individuals have been made to feel different, and 43% have been affected by bullying. In food contexts, 60% of peanut-allergic children, 71% of parents and caregivers, and 56% of peanut-allergic adults experienced anxiety. In non-food contexts, 15% of peanut-allergic children, 11% of parents and caregivers, and 12% of peanut-allergic adults experienced peanut allergy-related anxiety.

Many of the Patient Advocacy Group Leaders Involved have First-Hand Experience with Food Allergy

Sue Barrowcliffe, General Manager of Aimmune Europe, stated that the Company is committed to learning from people's experiences with food allergies and applying those insights to its efforts to develop approved therapeutics. The work and results of the APPEAL collaboration have been especially inspiring. Barrowcliffe added that many of the patient advocacy group leaders involved have first-hand experience with food allergy, and their insights on behalf of the community were a tremendous help in identifying key issues to query.

About Peanut Allergy

Peanut allergy is a type of food allergy to peanuts. It is different from tree nut allergies. Physical symptoms of allergic reactions can include itchiness, urticaria, swelling, eczema, sneezing, asthma, abdominal pain, drop in blood pressure, diarrhea, and cardiac arrest. Anaphylaxis might as well occur. It is due to a type I hypersensitivity reaction of the immune system in susceptible individuals. The allergy is recognized as one of the most severe food allergies due to its prevalence, persistency, and potential severity of allergic reaction. Currently, there is no cure for peanut allergy.

About Aimmune Therapeutics, Inc.

Founded in 2011 and headquartered in Brisbane, California, Aimmune Therapeutics is a clinical-stage biopharmaceutical organization developing desensitization treatments to protect people with food allergies from the life-threatening consequences of accidental exposures to their allergens.

Stock Performance Snapshot

May 31, 2018 - At Thursday's closing bell, Aimmune Therapeutics' stock climbed 1.22%, ending the trading session at $33.09.

Volume traded for the day: 307.99 thousand shares.

Stock performance in the last month ? up 5.58%; previous three-month period ? up 0.88%; and past twelve-month period ? up 99.34%

After yesterday's close, Aimmune Therapeutics' market cap was at $1.95 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors